Yaoming Kant's revenue increased by 68.52%in the first half of the year, and the stock price of China -Europe Fund plus the stock price fell 5.86%

On the evening of July 26, CRO leader Yao Kangde (603259.SH) disclosed the semi -annual report.

According to the financial report, in the first half of this year, Yin Ming Kant realized operating income of 17.756 billion yuan, an increase of 68.52%year -on -year; net profit attributable to the mother was 4.636 billion yuan, an increase of 73.29%year -on -year; the basic earnings per share were 1.59 yuan. During the period, the profit amount has set the highest level of history at the same time.

It is not enough. What has made many retail investors circling is that after the release of the semi -annual report, Yaoming Kangde's stock price not only did not boost, but declined sharply. On July 27, Yao Ming Kant opened slightly lower, and after the opening, it fell sharply. As of the atmosphere, the company's A -share stock price fell 5.86%to 95.61 yuan.

At the same time, the stock price of Yaoming Kangde Hong Kong also fell simultaneously, with a decline of nearly 5%. Driven by this, Kailey, Botten, Zhaoyan New Pharmaceutical, and Tiger Medicine have fallen with CRO concepts.

According to the semi -annual report, as of the end of June 2022, the number of shareholders of Yaoming Kangde was 216,400, an increase of 9,761 households. In the second quarter, some funds, especially the China -Europe Medical and Health Fund, continued to increase their positions. As for what the market was worried about, in addition to the announcement of the controlling shareholders' announcement, the growth rate of revenue may be difficult to maintain in the future. (Company research room big health group)

- END -